Skip to main content
. 2012 Sep 20;12:127. doi: 10.1186/1471-230X-12-127

Table 1.

Patient characteristics

Group
 Level 1
 Level 2
 Level 3
CDDP (mg/m2)
 35
 50
 65
Case number 1 2 3 4 5 6 7 8 9
Age (years)
 80
 62
 80
 78
 61
 80
 63
 79
 80
Gender (M, Male/F, Female)
 M
 M
 M
 M
 M
 M
 M
 F
 F
Performance status
 1
 0
 0
 0
 0
 0
 0
 0
 0
HBV infection
 -
 -
 -
 -
 -
 -
 +
 -
 -
HCV infection
 +
 +
 -
 -
 -
 +
 -
 +
 -
Alcohol
 -
 -
 +
 +
 +
 -
 -
 -
 -
Autoimmune hepatitis
 -
 -
 -
 -
 -
 -
 -
 -
 +
Child-Pugh Score
 6
 6
 5
 6
 6
 7
 5
 6
 6
Recurrence (Y, Yes/N, No)
 Y
 Y
 Y
 Y
 Y
 Y
 Y
 Y
 Y
Interval to previous therapy (M)
 6
 8
 6
 23
 10
 21
 13
 19
 3
Previous therapy
 TACE
 TAC
 TACE
 TACE
 TAC
 TACE
 TAC
 TACE
 TACE
History of CDDP Administration
 Y
 Y
 N
 Y
 Y
 Y
 Y
 Y
 Y
Number of tumors
 3
 2
 1
 >5
 >5
 4
 4
 >5
 >5
Maximum tumor size (mm)
 15
 15
 14
 20
 10
 34
 24
 10
 30
Vascular invasion (Y, Yes/N, No)
 N
 N
 N
 N
 N
 N
 N
 N
 N
Metastasis (Y, Yes/N, No)
 N
 N
 N
 N
 N
 N
 N
 N
 N
Stage (UICC)
 II
 II
 I
 II
 II
 II
 II
 II
 II
Tumor location (PAMLC)
 PA
 ML
 ML
 AM
 ML
 M
 P
 A
 PA
BSA (m2)
 1.486
 1.6
 1.457
 1.5
 1.72
 1.68
 1.415
 1.538
 1.538
Ccr (ml/min)
 68
 118
 75
 89
 121
 92
 83
 95
 85
CDDP (mg/body)
 52
 56
 51
 75
 86
 84
 92
 100
 100
Miriplatin (mg/body) 86 18 80 120 60 60 74 100 120

TACE, transarterial chemoembolization; TAC, transarterial chemotherapy. Tumour location: P, posterior segment; A, anterior segment; M, medial segment; L, lateral segment; C, caudal segment. BSA, body surface area; Ccr, creatinine clearance.